Dolasetron
Serotonin-3 Receptor Antagonist — ALIMENTARY TRACT AND METABOLISM
Also known as: anemet, anzemet, anzemet hydrate, dolasetron mesilate, dolasetron mesylate, dolasetron mesylate hydrate, dolasetron methanesulfonate hydrate, MDL 73,147EF
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Dolasetron is an ofm drug in the Serotonin-3 Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 1997. Its mechanism of action is classified as Serotonin 3 Receptor Antagonists. DrugCentral lists 2 molecular targets, including HTR3A and KCNH2. Recorded indications include Post-Operative Nausea and Vomiting and Prevention of Post-Operative Nausea and Vomiting.
- Approval status: ofm (first approved 1997 by the FDA).
- Drug class: Serotonin-3 Receptor Antagonist.
- Mechanism of action: Serotonin 3 Receptor Antagonists.
- Molecular targets: HTR3A and KCNH2 (2 listed in DrugCentral).
- Indications: Post-Operative Nausea and Vomiting and Prevention of Post-Operative Nausea and Vomiting.
- ATC code: A04AA04 (Serotonin (5HT3) antagonists).
- Molecular formula: C19H20N2O3; molecular weight 324.38 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Post-Operative Nausea and Vomiting
- Prevention of Post-Operative Nausea and Vomiting
Contraindications (12)
- Atrioventricular Conduction Defect
- Bradycardia
- Chemotherapy-induced nausea and vomiting
- Chronic heart failure
- Congenital long QT syndrome
- Doxorubicin Induced Cardiomyopathy
- Heart block
- Hypokalemia
- Hypomagnesemia
- Kidney disease
- Prolonged QT interval
- Torsades de pointes
Mechanism & targets
| Mechanism of action (MoA) | Serotonin 3 Receptor Antagonists |
|---|---|
| Established pharmacologic class | Serotonin-3 Receptor Antagonist |
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| 5-hydroxytryptamine receptor 3A | HTR3A | antagonist | Ki 7.70 |
| Potassium voltage-gated channel subfamily H member 2 | KCNH2 | unknown | IC50 5.23 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1997-09-11 | FDA | — | SANOFI AVENTIS US |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A04AA04 | ALIMENTARY TRACT AND METABOLISM › ANTIEMETICS AND ANTINAUSEANTS › ANTIEMETICS AND ANTINAUSEANTS › Serotonin (5HT3) antagonists |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Death | 385.6 |
| Disease progression | 96.0 |
| Off label use | 95.3 |
| Fatigue | 79.8 |
| Nausea | 68.9 |
| Asthenia | 48.6 |
| Myelosuppression | 38.4 |
Chemical structure
| Molecular formula | C19H20N2O3 |
|---|---|
| Molecular weight | 324.38 g/mol |
| CAS number | 115956-12-2 |
| InChIKey | UKTAZPQNNNJVKR-MMUVGSQPSA-N |
| PubChem CID | 3033818 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Dolasetron used for?
DrugCentral lists the following indications for Dolasetron: Post-Operative Nausea and Vomiting and Prevention of Post-Operative Nausea and Vomiting.
How does Dolasetron work?
Dolasetron is classified as Serotonin 3 Receptor Antagonists; its molecular targets in DrugCentral include HTR3A (antagonist) and KCNH2.
When was Dolasetron first approved?
Dolasetron was first approved by the FDA in 1997.
What drug class does Dolasetron belong to?
Dolasetron is in the Serotonin-3 Receptor Antagonist class.
What is the chemical formula of Dolasetron?
Dolasetron has the molecular formula C19H20N2O3 and a molecular weight of 324.38 g/mol.
Browse: all drugs starting with D · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 3931 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2368924 — compound record and bioactivity
- PubChem CID 3033818 — chemical identifiers
- DrugBank DB00757 — drug record
- FDA UNII 82WI2L7Q6E — substance identity
- DailyMed: FDA labels for Dolasetron — current prescribing information (label search)
- UniProt P46098 (HTR3A) — target protein
- UniProt Q12809 (KCNH2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.